Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel
Open Access
- 19 July 2024
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (7) , e23257
Abstract
Gene panel sequencing has become a common diagnostic tool for detecting somatically acquired mutations in myeloid neoplasms. However, many panels have restricted content, provide insufficient sensitivity levels, or lack clinically validated workflows. We here describe the development and validation of the Genomic Medicine Sweden myeloid gene panel (GMS‐MGP), a capture‐based 191 gene panel including mandatory genes in contemporary guidelines as well as emerging candidates. The GMS‐MGP displayed uniform coverage across all targets, including recognized difficult GC‐rich areas. The validation of 117 previously described somatic variants showed a 100% concordance with a limit‐of‐detection of a 0.5% variant allele frequency (VAF), achieved by utilizing error correction and filtering against a panel‐of‐normals. A national interlaboratory comparison investigating 56 somatic variants demonstrated highly concordant results in both detection rate and reported VAFs. In addition, prospective analysis of 323 patients analyzed with the GMS‐MGP as part of standard‐of‐care identified clinically significant genes as well as recurrent mutations in less well‐studied genes. In conclusion, the GMS‐MGP workflow supports sensitive detection of all clinically relevant genes, facilitates novel findings, and is, based on the capture‐based design, easy to update once new guidelines become available. The GMS‐MGP provides an important step toward nationally harmonized precision diagnostics of myeloid malignancies.Keywords
Funding Information
- Science for Life Laboratory
- Linköpings Universitet
- Lunds Universitet
- Karolinska Institutet
- Umeå Universitet
- Uppsala Universitet
- Örebro Universitet
- Socialdepartementet
- Region Skåne
- Västra Götalandsregionen
- Region Östergötland
- Region Uppsala
- Region Örebro län
This publication has 53 references indexed in Scilit:
- Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing AssayThe Journal of Molecular Diagnostics, 2021
- Next-Generation Sequencing in High-Sensitive Detection of Mutations in TumorsThe Journal of Molecular Diagnostics, 2020
- Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialThe Lancet Haematology, 2020
- Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion GenesThe Journal of Molecular Diagnostics, 2020
- Applications and analysis of targeted genomic sequencing in cancer studiesComputational and Structural Biotechnology Journal, 2019
- Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumoursNature, 2018
- Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics PipelinesThe Journal of Molecular Diagnostics, 2018
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerThe Journal of Molecular Diagnostics, 2017
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Strategy for Robust Detection of Insertions, Deletions, and Point Mutations in CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing TechnologyThe Journal of Molecular Diagnostics, 2011